Drug Trial Radar · NCT06847191
NE3107 in Adults With Neurological Symptoms of Long COVID
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
203
Actual
Start
Apr 29, 2025
Primary completion
Aug 6, 2026
Study completion Sep 2, 2026
Sponsor
- Lead sponsor
- BioVie Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. This study is designed as a signal-seeking proof-of-concept Phase 2 study. The primary outcome is intended for estimation and hypothesis generation rather than formal hypothesis testing. No single endpoint is designated as definitive for study success. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call
Conditions
- Long COVID
Interventions
NE3107Drug
20 mg Capsule
PlaceboDrug
placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in performance on the Cogstate Cognition battery*Time frame: 12 Weeks
- Change from Baseline in PROMIS Cognitive Function Short Form 8a (SF-8a)Time frame: 12 Weeks
- Change from Baseline in PROMIS Fatigue Short Form 13a (SF-13a)Time frame: 12 Weeks
- Change from Baseline in PROMIS Sleep Disturbance Short Form 8a (SF-8a)Time frame: 12 Weeks
- Change from Baseline in SF-12 Health Survey (Physical Component Scores)Time frame: 12 Weeks
- Change from Baseline in SF-12 Health Survey (Mental Component Scores)Time frame: 12 Weeks
- Change from Baseline in DePaul Symptom Questionnaire (DSQ) Post-Exertional MalaiseTime frame: 12 Weeks
- Composite Benefit ScoreTime frame: 12 Weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California
UCSF
San Francisco, California
University of Colorado
Aurora, Colorado
Yale University
New Haven, Connecticut
Clinical Trial Site
Jacksonville, Florida
Centricity Research
Columbus, Georgia
Illinois Research Network University of Illinois at Chicago
Chicago, Illinois
Northwestern University
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Norton Infectious Disease Institute
Louisville, Kentucky
Jadestone Clinical Research
Silver Spring, Maryland
Clinical Trial Site
Farmington Hills, Michigan
Mayo Clinic
Rochester, Minnesota
Icahn School of Medicine at Mount Sinai
New York, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Zenos Clinical Research
Dallas, Texas
University of Texas health Science Center at San Antonio
San Antonio, Texas
Chronicle Bio Inc.
Park City, Utah
Swedish Center for Research and Innovation
Seattle, Washington
West Virginia University
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.